Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma

Keito Suto; Norio Takei; Keito Yokoyama; Masahiro Chiba; Takashi Ishio; Michiyuki Maeda; Hideki Goto; Tomoyuki Endo; Takanori Teshima; Yibin Yang; Masao Nakagawa

doi:10.1038/s41375-024-02441-1

Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma

Keito Suto
, Norio Takei
, Keito Yokoyama
, Masahiro Chiba
, Takashi Ishio
, Michiyuki Maeda
, Hideki Goto
, Tomoyuki Endo
, Takanori Teshima
, Yibin Yang
, Masao Nakagawa

Hokkaido University
Kyoto University

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Abstract

(Figure presented.)

Original language	English
Pages (from-to)	243-247
Number of pages	5
Journal	Leukemia
Volume	39
Issue number	1
DOIs	https://doi.org/10.1038/s41375-024-02441-1
State	Published - Jan 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/s41375-024-02441-1

Cite this

@article{1c8b563b995c4cecb0eea23c5842d9e4,

title = "Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma",

abstract = "(Figure presented.)",

author = "Keito Suto and Norio Takei and Keito Yokoyama and Masahiro Chiba and Takashi Ishio and Michiyuki Maeda and Hideki Goto and Tomoyuki Endo and Takanori Teshima and Yibin Yang and Masao Nakagawa",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Nature Limited 2024.",

year = "2025",

month = jan,

doi = "10.1038/s41375-024-02441-1",

language = "English",

volume = "39",

pages = "243--247",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Springer Nature",

number = "1",

}

TY - JOUR

T1 - Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma

AU - Suto, Keito

AU - Takei, Norio

AU - Yokoyama, Keito

AU - Chiba, Masahiro

AU - Ishio, Takashi

AU - Maeda, Michiyuki

AU - Goto, Hideki

AU - Endo, Tomoyuki

AU - Teshima, Takanori

AU - Yang, Yibin

AU - Nakagawa, Masao

PY - 2025/1

Y1 - 2025/1

N2 - (Figure presented.)

AB - (Figure presented.)

UR - https://www.scopus.com/pages/publications/85207023612

U2 - 10.1038/s41375-024-02441-1

DO - 10.1038/s41375-024-02441-1

M3 - Article

C2 - 39433928

AN - SCOPUS:85207023612

SN - 0887-6924

VL - 39

SP - 243

EP - 247

JO - Leukemia

JF - Leukemia

IS - 1

ER -

Genome-wide CRISPR screen identifies MAD2L1BP and ANAPC15 as targets for brentuximab vedotin sensitivity in CD30+ peripheral T-cell lymphoma

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this